Table 3 Chi square analysis for pre-RT and post-RT NLR
| Â | Pre-RT NLR | Post-RT NLR | ||||
|---|---|---|---|---|---|---|
p value | < 4.0 | ≥ 4.0 | p value | < 4.0 | ≥ 4.0 | |
Sex | ||||||
 Male | 0.234 | 758 (90.9) | 76 (9.1) | 0.024 | 502 (57.0) | 378 (43.0) |
 Female | 417 (92.3) | 35 (7.7) | 298 (62.7) | 177 (37.3) | ||
icT | ||||||
 T1/2 | 0.557 | 107 (91.5) | 10 (8.5) | 0.024 | 88 (67.2) | 43 (32.8) |
 T3/4 | 1056 (91.3) | 101 (8.7) | 101 (57.9) | 510 (42.1) | ||
icN | ||||||
 N0 | 0.453 | 211 (90.9) | 21 (9.1) | 0.307 | 155 (61.5) | 97 (38.5) |
 N1/2 | 915 (91.4) | 86 (8.6) | 605 (57.5) | 444 (42.3) | ||
RT modality | ||||||
 3D-CRT | 0.48 | 732 (91.3) | 70 (8.7) | < 0.001 | 532 (62.5) | 319 (37.5) |
 Tomotherapy | 443 (91.5) | 41 (8.5) | 268 (53.2) | 236 (46.8) | ||
ypT | ||||||
 T1/2 | 0.004 | 599 (93.6) | 42 (6.4) | < 0.001 | 427 (63.9) | 241 (36.1) |
 T3/4 | 573 (89.3) | 69 (10.7) | 371 (54.3) | 312 (45.7) | ||
ypN | ||||||
 N0 | 0.386 | 855 (91.5) | 79 (8.5) | 0.15 | 574 (58.5) | 407 (41.5) |
 N1/2 | 318 (90.9) | 32 (9.1) | 224 (60.2) | 148 (39.8) | ||
Adjuvant chemotherapy | ||||||
 No | 0.389 | 539 (91.0) | 53 (9.0) | 0.001 | 343 (54.6) | 285 (45.4) |
 Yes | 636 (91.6) | 58 (8.4) | 457 (62.9) | 270 (37.1) | ||
RT fractionation | ||||||
 LCRT | 0.513 | 1147 (91.3) | 109 (8.7) | 0.012 | 776 (58.6) | 549 (41.4) |
 SCRT | 28 (93.3) | 2 (6.7) | 24 (80.0) | 6 (20.0) | ||